Reports
Sale
Gallbladder Cancer Market Share, Trends, Outlook, Analysis: By Type: Stage I, Stage II, Stage III, Stage IV; By Diagnosis Type: Physical Examination, Liver Function Test, Blood Test, CT Scan, Ultrasound, Others; By Treatment; By Route of Administration; By End User; Regional Analysis; Market Dynamics: SWOT Analysis; Supplier Landscape; 2024-2032
Gallbladder Cancer Market Outlook
The gallbladder cancer market size was valued at USD 87.57 million in 2023, driven by the increasing research and development activities for new treatment among people across the 7 major markets. The market size is anticipated to grow at a CAGR of 5.56% during the forecast period of 2024-2032 to achieve a value of USD 142.5 million by 2032.
Gallbladder Cancer: Introduction
Gallbladder cancer originates from abnormal cell growth within the gallbladder, a small, pear-shaped organ located beneath the liver on the right side of the abdomen. Responsible for storing bile, a digestive fluid produced by the liver, the gallbladder plays a crucial role in the digestive process. Though uncommon, gallbladder cancer poses a significant challenge due to its tendency to remain asymptomatic in its early stages, often leading to late detection and a poor prognosis. The insidious nature of this cancer is exacerbated by its subtle symptoms or the absence thereof, allowing it to progress unnoticed.
Common signs such as upper right abdominal pain, bloating, unexplained weight loss, and jaundice, characterized by yellowing of the skin and eyes, might indicate the presence of gallbladder cancer, but these indicators often manifest in later stages, complicating timely diagnosis and treatment.
Gallbladder Cancer Market Analysis
The market for gallbladder cancer treatment is witnessing a transformative phase, driven by several key factors. The rise in demand and emphasis on targeted therapy treatments is further anticipated to bolster the gallbladder cancer market growth. For example, Gemcitabine, a combination therapy, has shown promising results, indicating an increased response rate compared to traditional treatments using 5-FU alone. The efficacy of gemcitabine in conjunction with cis-platinum and capecitabine highlights its potential as a viable treatment option.
Pembrolizumab has also shown positive results in tumours with high microsatellite instability/deficient mismatch repair, and entrectinib, a tyrosine kinase inhibitor, has potential use in NTRK gene fusion-positive tumours, providing a new pathway for gallbladder cancer treatment. These developments signify a shift towards more targeted and potentially more effective therapies, exhibiting hopeful market growth.
Gallbladder Cancer Market Segmentations
Market Breakup by Type
- Stage I
- Stage II
- Stage III
- Stage IV
Market Breakup by Diagnosis Type
- Physical Examination
- Liver Function Test
- Blood Test
- CT Scan
- Ultrasound
- Percutaneous Transhepatic Cholangiography (PTC)
- Endoscopic Retrograde Cholangiopancreatography (ERC)
- Magnetic Resonance Imaging (MRI)
- Endoscopic ultrasound (EUS)
- Laparoscopy
- Biopsy
Market Breakup by Treatment
- Surgery
- Radiation Therapy
- Chemotherapy
- Immunotherapy
Market Breakup by Route of Administration
- Oral
- Injections
Market Breakup by End User
- Hospitals
- Gynaecology Clinics
- Academic and Research Centers
Market Breakup by Region
- United States
- EU-4 and the United Kingdom
- Germany
- France
- Italy
- Spain
- United Kingdom
- Japan
Gallbladder Cancer Market Overview
The market is experiencing significant growth driven by the rising prevalence of gallbladder cancer, especially among the geriatric population, which underscores the urgency for precision treatments. The statistics projected by the American Cancer Society for 2023 in the United States display concern by mentioning that a substantial number of new cases and related deaths are anticipated to occur in 2023. This surge in cases, particularly gallbladder cancers, signifies an unmet need for more effective therapies and diagnostic tools, further bolstering the gallbladder cancer market demand. The market is poised for further growth, primarily fueled by advancements in diagnostic technologies and the emergence of innovative therapeutics in the market.
The United States has been dominating the markets and is expected to lead the market in forecast period. This growth can be attributed to the increasing incidence of gallbladder cancer, the presence of key industry players, and the robust healthcare infrastructure in the region. Rising research and development continue to pave the way for novel interventions and diagnostic methods, contributing significantly to the rising gallbladder cancer market share, addressing critical healthcare gaps, and offering hope to affected individuals.
Gallbladder Cancer Market: Competitor Landscape
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
- Cipla Inc.
- Bristol-Myers Squibb Company
- Eli Lilly and Company
- Pfizer Inc.
- F. Hoffmann-La Roche Ltd
- Sanofi
- OncoTherapy Science, Inc.
- Intuitive Surgical
- Sun Pharmaceutical Industries
- GLS Pharma Ltd.
- Symmetry Surgical Inc.
- CONMED Corporation
- Olympus Corporation
- Boston Scientific Corporation
Please note that this only represents a partial list of companies, and the complete list has been provided in the report.
Key Highlights of the Report
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Type |
|
| Breakup by Diagnosis Type |
|
| Breakup by Treatment |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.
1 Preface
1.1 Objectives of the Study
1.2 Key Assumptions
1.3 Report Coverage – Key Segmentation and Scope
1.4 Research Methodology
2 Executive Summary
3 Gallbladder Cancer Overview
3.1 Guidelines and Stages
3.2 Pathophysiology
3.3 Screening and Diagnosis
3.4 Treatment Pathway
4 Patient Profile
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Gallbladder Cancer Epidemiology Analysis – 7MM
5.1 7MM Epidemiology Scenario Overview (2017-2032)
5.2 United States Gallbladder Cancer Epidemiology Forecast (2017-2032)
5.3 EU-4 and United Kingdom Gallbladder Cancer Epidemiology Forecast (2017-2032)
5.3.1 Germany Gallbladder Cancer Epidemiology Forecast (2017-2032)
5.3.2 France Gallbladder Cancer Epidemiology Forecast (2017-2032)
5.3.3 Italy Gallbladder Cancer Epidemiology Forecast (2017-2032)
5.3.4 Spain Gallbladder Cancer Epidemiology Forecast (2017-2032)
5.3.5 United Kingdom Gallbladder Cancer Epidemiology Forecast (2017-2032)
5.4 Japan Gallbladder Cancer Epidemiology Forecast (2017-2032)
6 Gallbladder Cancer Market Overview – 7MM
6.1 Gallbladder Cancer Market Historical Value (2017-2023)
6.2 Gallbladder Cancer Market Forecast Value (2024-2032)
7 Gallbladder Cancer Market Landscape – 7MM
7.1 Gallbladder Cancer Developers Landscape
7.1.1 Analysis by Year of Establishment
7.1.2 Analysis by Company Size
7.1.3 Analysis by Region
7.2 Gallbladder Cancer Product Landscape
7.2.1 Analysis by Type
7.2.2 Analysis by Treatments
7.2.3 Analysis by Route of Administration
8 Gallbladder Cancer Challenges and Unmet Needs
8.1 Treatment Pathway Challenges
8.2 Compliance and Drop-Out Analysis
8.3 Awareness and Prevention Gaps
9 Cost of Treatment
10 Gallbladder Cancer Market Dynamics
10.1 Market Drivers and Constraints
10.2 SWOT Analysis
10.3 Porter’s Five Forces Model
10.4 Key Demand Indicators
10.5 Key Price Indicators
10.6 Industry Events, Initiatives, and Trends
10.7 Value Chain Analysis
11 Gallbladder Cancer Market Segmentation – 7MM
11.1 Gallbladder Cancer Market by Type
11.1.1 Market Overview
11.1.2 Stage I
11.1.3 Stage II
11.1.4 Stage III
11.1.5 Stage IV
11.2 Gallbladder Cancer Market by Diagnosis Type
11.2.1 Market Overview
11.2.2 Physical Examination
11.2.3 Liver Function Test
11.2.4 Blood Test
11.2.5 CT Scan
11.2.6 Ultrasound
11.2.7 Percutaneous Transhepatic Cholangiography (PTC)
11.2.8 Endoscopic Retrograde Cholangiopancreatography (ERC)
11.2.9 Magnetic Resonance Imaging (MRI)
11.2.10 Endoscopic ultrasound (EUS)
11.2.11 Laparoscopy
11.2.12 Biopsy
11.3 Gallbladder Cancer Market by Treatment
11.3.1 Market Overview
11.3.2 Surgery
11.3.3 Radiation Therapy
11.3.4 Chemotherapy
11.3.5 Immunotherapy
11.4 Gallbladder Cancer Market by Route of Administration
11.4.1 Market Overview
11.4.2 Oral
11.4.3 Injections
11.5 Gallbladder Cancer Market by End User
11.5.1 Market Overview
11.5.2 Hospitals
11.5.3 Gynaecology Clinics
11.5.4 Academic and Research Centers
11.6 Gallbladder Cancer Market by Region
11.6.1 Market Overview
11.6.2 United States
11.6.3 EU-4 and the United Kingdom
11.6.3.1 Germany
11.6.3.2 France
11.6.3.3 Italy
11.6.3.4 Spain
11.6.3.5 United Kingdom
11.6.4 Japan
12 United States Gallbladder Cancer Market
12.1 Gallbladder Cancer Market Historical Value (2017-2023)
12.2 Gallbladder Cancer Market Forecast Value (2024-2032)
12.3 Gallbladder Cancer Market by Disease Type
12.4 Gallbladder Cancer Market by Treatment Type
13 EU-4 and United Kingdom Gallbladder Cancer Market
13.1 Gallbladder Cancer Market Historical Value (2017-2023)
13.2 Gallbladder Cancer Market Forecast Value (2024-2032)
13.3 Germany Gallbladder Cancer Market Overview
13.3.1 Gallbladder Cancer Market by Disease Type
13.3.2 Gallbladder Cancer Market by Treatment Type
13.4 France Gallbladder Cancer Market Overview
13.4.1 Gallbladder Cancer Market by Disease Type
13.4.2 Gallbladder Cancer Market by Treatment Type
13.5 Italy Gallbladder Cancer Market Overview
13.5.1 Gallbladder Cancer Market by Disease Type
13.5.2 Gallbladder Cancer Market by Treatment Type
13.6 Spain Gallbladder Cancer Market Overview
13.6.1 Gallbladder Cancer Market by Disease Type
13.6.2 Gallbladder Cancer Market by Treatment Type
13.7 United Kingdom Gallbladder Cancer Market Overview
13.7.1 Gallbladder Cancer Market by Disease Type
13.7.2 Gallbladder Cancer Market by Treatment Type
14 Japan Gallbladder Cancer Market
14.1 Gallbladder Cancer Market Historical Value (2017-2023)
14.2 Gallbladder Cancer Market Forecast Value (2024-2032)
14.3 Gallbladder Cancer Market by Disease Type
14.4 Gallbladder Cancer Market by Treatment Type
15 Patent Analysis
15.1 Analysis by Type of Patent
15.2 Analysis by Publication year
15.3 Analysis by Issuing Authority
15.4 Analysis by Patent Age
15.5 Analysis by CPC Analysis
15.6 Analysis by Patent Valuation
15.7 Analysis by Key Players
16 Grants Analysis
16.1 Analysis by year
16.2 Analysis by Amount Awarded
16.3 Analysis by Issuing Authority
16.4 Analysis by Grant Application
16.5 Analysis by Funding Institute
16.6 Analysis by NIH Departments
16.7 Analysis by Recipient Organization
17 Clinical Trials Analysis
17.1 Analysis by Trial Registration Year
17.2 Analysis by Trial Status
17.3 Analysis by Trial Phase
17.4 Analysis by Therapeutic Area
17.5 Analysis by Geography
18 Funding Analysis
18.1 Analysis by Funding Instances
18.2 Analysis by Type of Funding
18.3 Analysis by Funding Amount
18.4 Analysis by Leading Players
18.5 Analysis by Leading Investors
18.6 Analysis by Geography
19 Partnership and Collaborations Analysis
19.1 Analysis by Partnership Instances
19.2 Analysis by Type of Partnership
19.3 Analysis by Leading Players
19.4 Analysis by Geography
20 Supplier Landscape
20.1 Cipla Inc.
20.1.1 Financial Analysis
20.1.2 Product Portfolio
20.1.3 Demographic Reach and Achievements
20.1.4 Mergers and Acquisition
20.1.5 Certifications
20.2 Bristol-Myers Squibb Company
20.2.1 Financial Analysis
20.2.2 Product Portfolio
20.2.3 Demographic Reach and Achievements
20.2.4 Mergers and Acquisition
20.2.5 Certifications
20.3 Eli Lilly and Company
20.3.1 Financial Analysis
20.3.2 Product Portfolio
20.3.3 Demographic Reach and Achievements
20.3.4 Mergers and Acquisition
20.3.5 Certifications
20.4 Pfizer Inc.
20.4.1 Financial Analysis
20.4.2 Product Portfolio
20.4.3 Demographic Reach and Achievements
20.4.4 Mergers and Acquisition
20.4.5 Certifications
20.5 F. Hoffmann-La Roche Ltd
20.5.1 Financial Analysis
20.5.2 Product Portfolio
20.5.3 Demographic Reach and Achievements
20.5.4 Mergers and Acquisition
20.5.5 Certifications
20.6 Sanofi
20.6.1 Financial Analysis
20.6.2 Product Portfolio
20.6.3 Demographic Reach and Achievements
20.6.4 Mergers and Acquisition
20.6.5 Certifications
20.7 OncoTherapy Science, Inc.
20.7.1 Financial Analysis
20.7.2 Product Portfolio
20.7.3 Demographic Reach and Achievements
20.7.4 Mergers and Acquisition
20.7.5 Certifications
20.8 Intuitive Surgical
20.8.1 Financial Analysis
20.8.2 Product Portfolio
20.8.3 Demographic Reach and Achievements
20.8.4 Mergers and Acquisition
20.8.5 Certifications
20.9 Sun Pharmaceutical Industries
20.9.1 Financial Analysis
20.9.2 Product Portfolio
20.9.3 Demographic Reach and Achievements
20.9.4 Mergers and Acquisition
20.9.5 Certifications
20.10 GLS pharma ltd.
20.10.1 Financial Analysis
20.10.2 Product Portfolio
20.10.3 Demographic Reach and Achievements
20.10.4 Mergers and Acquisition
20.10.5 Certifications
20.11 Symmetry Surgical Inc.
20.11.1 Financial Analysis
20.11.2 Product Portfolio
20.11.3 Demographic Reach and Achievements
20.11.4 Mergers and Acquisition
20.11.5 Certifications
20.12 CONMED Corporation
20.12.1 Financial Analysis
20.12.2 Product Portfolio
20.12.3 Demographic Reach and Achievements
20.12.4 Mergers and Acquisition
20.12.5 Certifications
20.13 Olympus Corporation
20.13.1 Financial Analysis
20.13.2 Product Portfolio
20.13.3 Demographic Reach and Achievements
20.13.4 Mergers and Acquisition
20.13.5 Certifications
20.14 Boston Scientific Corporation
20.14.1 Financial Analysis
20.14.2 Product Portfolio
20.14.3 Demographic Reach and Achievements
20.14.4 Mergers and Acquisition
20.14.5 Certifications
21 Gallbladder Cancer Market - Distribution Model (Additional Insight)
21.1 Overview
21.2 Potential Distributors
21.3 Key Parameters for Distribution Partner Assessment
22 Key Opinion Leaders (KOL) Insights (Additional Insight)
23 Company Competitiveness Analysis (Additional Insight)
23.1 Very Small Companies
23.2 Small Companies
23.3 Mid-Sized Companies
23.4 Large Companies
23.5 Very Large Companies
24 Payment Methods (Additional Insight)
24.1 Government Funded
24.2 Private Insurance
24.3 Out-of-Pocket
*Additional insights provided are customisable as per client requirements.
Key Questions Answered in the Report
The market attained a value of about USD 87.57 million in 2023 in the 7 major markets, driven by the rising prevalence of gallbladder cancer in these regions.
The market is anticipated to grow at a CAGR of 5.56% during the forecast period of 2024-2032 and is likely to reach a market value of USD 142.5 million by 2032.
The rising prevalence of gallbladder cancer across the 7 major markets, rapid advancements in the treatment market, and rising disposable incomes are among the major drivers driving the market growth.
The market is further influenced by the rising demand and emphasis on targeted therapy treatments.
The major regions of the market include the United States, EU-4 and the United Kingdom, and Japan. EU-4 is divided into Germany, France, Italy, and Spain.
Gallbladder cancer types include stage I, stage II, stage III, and stage IV.
Treatments available in the market include surgery, radiation therapy, chemotherapy, and immunotherapy.
The condition can be diagnosed with the help of physical examination, liver function test, blood test, CT scan, ultrasound, Percutaneous Transhepatic Cholangiography (PTC), Endoscopic Retrograde Cholangiopancreatography (ERC), Magnetic Resonance Imaging (MRI), Endoscopic ultrasound (EUS), and laparoscopy, biopsy, among others.
Oral and injections are the routes of administration in the market.
End users include hospitals, gynaecology clinics, and academic and research centers.
Key players involved in the market are Cipla Inc., Bristol-Myers Squibb Company, Eli Lilly and Company, Pfizer Inc., F. Hoffmann-La Roche Ltd, Sanofi, OncoTherapy Science, Inc., Intuitive Surgical, Sun Pharmaceutical Industries, GLS Pharma Ltd., Symmetry Surgical Inc., CONMED Corporation, Olympus Corporation, ad Boston Scientific Corporation.
Purchase Options 10% off
Call us
Purchase Full Report
Mini Report
$ 3299
$2999
-
Selected Sections, One User
-
Printing Not Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Single User License
$ 6599
$5999
-
All Sections, One User
-
One Print Allowed
-
Email Delivery in PDF
-
Free Limited Customisation -
Post Sales Analyst Support -
50% Discount on Next Update
Five User License
$ 8799
$7999
-
All Sections, Five Users
-
Five Prints Allowed
-
Email Delivery in PDF
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Corporate License
$ 9899
$8999
-
All Sections, Unlimited Users
-
Unlimited Prints Allowed
-
Email Delivery in PDF + Excel
-
Free Limited Customisation
-
Post Sales Analyst Support
-
50% Discount on Next Update
Any Question? Speak With An Analyst
View A Sample
Did You Miss Anything, Ask Now
Why Expert Market Research?
Right People
We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.
Right Methodology
We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.
Right Price
We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.
Right Support
Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.
NEWSLETTER